Retinitis Pigmentosa News and Research RSS Feed - Retinitis Pigmentosa News and Research

Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
French Ministry of Health approves financial support for Second Sight Argus II Retinal Prosthesis System

French Ministry of Health approves financial support for Second Sight Argus II Retinal Prosthesis System

Second Sight Medical Products Inc. today announces that the French Ministry of Health has officially approved financial support for the Argus II Retinal Prosthesis System. Through the Forfait Innovation scheme, the French Government will pay for the first wave of groundbreaking treatment for 36 patients with severe to total sight loss due to retinitis pigmentosa (RP) in France. [More]

Retina's Alpha IMS microchip receives NUB innovation status from Germany statutory health insurance

Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced that the Company's Alpha IMS microchip was granted NUB innovation status and will now be reimbursed by Germany's statutory health insurance system. [More]
Iodine supplement can reduce central foveal swelling in RP patients with CME

Iodine supplement can reduce central foveal swelling in RP patients with CME

Cystoid macular edema (CME) is a common complication of retinitis pigmentosa (RP), a family of retinal diseases in which patients typically lose night and side vision first and then develop impaired central vision. CME can also decrease central vision. [More]
New chemical compound protects against blindness and diabetes in animals

New chemical compound protects against blindness and diabetes in animals

In a new study led by UC San Francisco scientists, a chemical compound designed to precisely target part of a crucial cellular quality-control network provided significant protection, in rats and mice, against degenerative forms of blindness and diabetes. [More]
New approach for developing personalized gene therapies to treat retinitis pigmentosa

New approach for developing personalized gene therapies to treat retinitis pigmentosa

Columbia University Medical Center researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss. [More]
Light-sensitive molecule enables noninvasive silencing of neurons

Light-sensitive molecule enables noninvasive silencing of neurons

Optogenetics, a technology that allows scientists to control brain activity by shining light on neurons, relies on light-sensitive proteins that can suppress or stimulate electrical signals within cells. This technique requires a light source to be implanted in the brain, where it can reach the cells to be controlled. [More]
University of Utah researcher to receive Nelson Trust Award for Retinitis Pigmentosa

University of Utah researcher to receive Nelson Trust Award for Retinitis Pigmentosa

Research to Prevent Blindness, a New York-based foundation, has announced that University of Utah researcher Wolfgang Baehr, Ph.D., will receive the Nelson Trust Award for Retinitis Pigmentosa-and an accompanying $100,000 to pursue new scientific leads to understand contributors to blindness. [More]
Auxilium Pharmaceuticals plans to merge with QLT

Auxilium Pharmaceuticals plans to merge with QLT

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, and QLT Inc., a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products, today announced that they have entered into a definitive agreement under which Auxilium plans to merge with QLT. [More]
Researchers create three-dimensional complement of human retinal tissue in a dish

Researchers create three-dimensional complement of human retinal tissue in a dish

Using a type of human stem cell, Johns Hopkins researchers say they have created a three-dimensional complement of human retinal tissue in the laboratory, which notably includes functioning photoreceptor cells capable of responding to light, the first step in the process of converting it into visual images. [More]
Researchers take step toward restoring natural, high-fidelity vision to blind people

Researchers take step toward restoring natural, high-fidelity vision to blind people

In laboratory tests, researchers have used electrical stimulation of retinal cells to produce the same patterns of activity that occur when the retina sees a moving object. Although more work remains, this is a step toward restoring natural, high-fidelity vision to blind people, the researchers say. [More]
Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Ocugen, Inc. and the University of Colorado today announced exclusive license agreements that allow for Ocugen to continue developing two drug candidates for the treatment for ophthalmology indications, and that one of the assets, OCU100, recombinant lens epithelium derived growth factor 1-326 (LEDGF1-326), received orphan-drug status from the U.S. Food and Drug Administration for treatment of retinitis pigmentosa (RP), a rare eye disease. [More]
RPB grants $500,000 to accelerate treatments for Retinitis Pigmentosa

RPB grants $500,000 to accelerate treatments for Retinitis Pigmentosa

Research to Prevent Blindness (RPB), the leading eye research foundation, is providing $500,000 to accelerate the development of treatments for Retinitis Pigmentosa (RP) -- a family of retinal diseases that progressively create extreme tunnel vision, loss of night vision and leave affected patients legally blind by the age of 40. [More]
Sanofi and Lilly announces agreement to pursue regulatory approval of Cialis

Sanofi and Lilly announces agreement to pursue regulatory approval of Cialis

Sanofi and Eli Lilly and Company today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). [More]
DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes. [More]
Scientists develop non-invasive technique to determine gene carriers  for retinitis pigmentosa

Scientists develop non-invasive technique to determine gene carriers for retinitis pigmentosa

Scientists have developed a non-invasive technique to determine if individuals carry a gene for an inherited eye disease known as retinitis pigmentosa. [More]
Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

Retinitis pigmentosa (RP) is a progressive eye disease that leads to untreatable blindness. The name of the disease derives from the fact that one of the areas affected by the disease is the retinal pigment epithelium (RPE) in the back of the eye. [More]
Second Sight's Argus II Retinal Prosthesis System selected for Forfait Innovation reimbursement

Second Sight's Argus II Retinal Prosthesis System selected for Forfait Innovation reimbursement

Second Sight Medical Products Inc. announces today that the Argus II Retinal Prosthesis System, the world’s first approved device intended to restore some functional vision for people suffering from blindness due to outer retinal degenerations, has become the first recipient of the French Government national healthcare reimbursement program entitled ‘Forfait Innovation’. [More]
Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Spark Therapeutics and Genable Technologies announced today that they have entered into a collaboration agreement for Genable's lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO adRP), GT038. [More]
Newly developed compound may allow blind see light

Newly developed compound may allow blind see light

Progressive degeneration of photoreceptors-the rods and cones of the eyes-causes blinding diseases such as retinitis pigmentosa and age-related macular degeneration. While there are currently no available treatments to reverse this degeneration, a newly developed compound allows other cells in the eye to act like photoreceptors. As described in a study appearing in the February 19 issue of the Cell Press journal Neuron, the compound may be a potential drug candidate for treating patients suffering from degenerative retinal disorders. [More]
Clinician scientist receives RPB Career Development Award to support eye research

Clinician scientist receives RPB Career Development Award to support eye research

The Harvard Medical School (HMS) Department of Ophthalmology has been granted a $250,000 Research to Prevent Blindness (RPB) Career Development Award to support eye research conducted by Jason I. Comander, M.D., Ph.D. The support will be provided over a four-year period. [More]